Merck & Co., Inc. (NYSE:MRK) Posts Quarterly Earnings Results, Beats Expectations By $0.40 EPS

Merck & Co., Inc. (NYSE:MRK) announced its quarterly earnings results on Thursday. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.09 by $0.40, FiscalAI reports. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter last year, the company posted $2.58 earnings per share. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year.

Here are the key takeaways from Merck & Co., Inc.’s conference call:

• Third-quarter revenue rose 5% to $18.1 billion, while Merck raised the midpoint of its 2026 revenue and EPS guidance to $66.8–$67.3 billion and $2.77–$2.82, respectively.
• Newer products continued to gain traction, including WINREVAIR, whose sales increased 94% to $694 million, and WELIREG, up 58% to $307 million; KEYTRUDA sales also grew 6% to $8.6 billion.
• Management highlighted encouraging pipeline progress, including positive phase III data for sac-TMT in endometrial cancer, favorable results for the individualized cancer vaccine intismeran in melanoma, and positive phase IIb data for tulisokibart in hidradenitis suppurativa.
• Management expects more than $2 billion of 2027 revenue headwinds from generic competition and loss of exclusivity affecting BRIDION, the JANUVIA family, and A​​DEMPAS, while KEYTRUDA growth is expected to moderate ahead of its eventual loss-of-exclusivity period.
• Merck expects 2027 to be another investment year, with operating expenses rising at a mid- to high-single-digit rate as it funds launches and pipeline development; vaccine utilization trends, pricing pressure outside the U.S., and policy changes in Germany remain areas to monitor.

Merck & Co., Inc. Price Performance

MRK traded up $4.24 on Friday, hitting $150.57. 5,400,515 shares of the company’s stock were exchanged, compared to its average volume of 10,642,463. The stock has a market cap of $371.47 billion, a price-to-earnings ratio of 120.25, a P/E/G ratio of 6.49 and a beta of 0.21. Merck & Co., Inc. has a fifty-two week low of $82.01 and a fifty-two week high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The firm has a 50-day moving average price of $146.89 and a 200-day moving average price of $126.49.

Insider Buying and Selling

In other news, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP David Maraldo sold 18,706 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock worth $29,977,783 over the last ninety days. Company insiders own 0.17% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on MRK. JPMorgan Chase & Co. raised their price target on Merck & Co., Inc. from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Monday, October 5th. Guggenheim boosted their price objective on shares of Merck & Co., Inc. from $170.00 to $171.00 and gave the company a “buy” rating in a research report on Friday. Wolfe Research raised their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 25th. Leerink Partners raised their price objective on Merck & Co., Inc. from $127.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Finally, Morgan Stanley dropped their target price on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating on the stock in a report on Wednesday, October 7th. Seventeen analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $152.96.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported third-quarter adjusted earnings of $2.49 per share, well above the $2.09 consensus estimate, while revenue rose 4.7% year over year to $18.09 billion, exceeding expectations. Merck tops quarterly estimates, hikes profit outlook
• Positive Sentiment: The company raised its 2026 outlook, with Keytruda—including the newer Qlex formulation—remaining a major growth driver. Newer products such as WINREVAIR are also scaling rapidly, helping offset pressure from older products and expected generic competition. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Merck presented favorable Phase 3 endometrial cancer data for KEYTRUDA, while sacituzumab tirumotecan also produced positive late-stage results. The FDA granted priority review to the latter’s application, potentially accelerating a future pipeline opportunity. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Guggenheim raised its price target to $171 and maintained a “buy” rating, signaling confidence in Merck’s earnings momentum and pipeline. Guggenheim analyst rating
• Neutral Sentiment: Merck continues to attract attention as a dividend stock, although investors should assess the sustainability of its payout alongside patent and product-concentration risks. Healthcare dividend analysis
• Negative Sentiment: Royal Bank of Canada cut its price target from $145 to $140 and retained a “sector perform” rating, implying downside from recent trading levels. Royal Bank of Canada rating
• Negative Sentiment: Investors remain concerned about generic competition and the looming patent cliff for Keytruda, Merck’s largest revenue contributor. A securities law firm has also announced an investigation related to prior company disclosures, adding a potential headline risk. Merck securities investigation

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.